People with multiple sclerosis fare about as well as other populations following SARS-CoV-2 infection, but ambulation disability and a few other factors raise the risk of a worse clinical course.
Magnetic resonance fingerprinting is improving lesion identification in epilepsy, brain microstructure evaluation in MS, and more. Two experts share the essentials on this emerging imaging advancement.
Some 2% to 4% of patients misdiagnosed with multiple sclerosis are eventually diagnosed with a genetic leukodystrophy. A new clinical cohort study offers much-needed guidance to help identify them.
A national survey of people living with MS reveals abundant opportunities for greater education about the FDA approval process and opportunities to bolster patients’ confidence in it.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
A pooled analysis of three randomized trials of nabiximols helps lay the groundwork for an FDA submission in 2021. Approval would yield the first novel treatment for spasticity in multiple sclerosis in many years.
This protein shows promise as a biomarker for use in early-stage therapeutic trials, but more work is needed. An expert panel has outlined what should be done next to rapidly realize its potential.
Traditional means of monitoring patients with MS are increasingly inadequate. The director of our MS program discusses emerging technologies and research studies to explore their roles.
Even as functional performance diminished, depressed patients with multiple sclerosis were not able to recognize the decline.
A national expert in stem cell therapies for multiple sclerosis shares an update on the technology’s promise and practical uncertainties in the latest installment of our Neuro Pathways podcast.
Up to 20% of multiple sclerosis diagnoses turn out to be inaccurate. A new multicenter study aims to reduce that number by bringing this new biomarker into the diagnostic mix.